What is Nemaura Medical Debt-to-Equity?
Nemaura Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $19.64 Mil. Nemaura Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Nemaura Medical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-17.83 Mil.
Nemaura Medical's debt to equity for the quarter that ended in Dec. 2023 was -1.10.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nemaura Medical's Debt-to-Equity or its related term are showing as below:
NMRD'
s Debt-to-Equity Range Over the Past 10 Years
Min: -5.28 Med: 0.46 Max: 41.18
Current: -1.1
During the past 10 years, the highest Debt-to-Equity Ratio of Nemaura Medical was 41.18. The lowest was -5.28. And the median was 0.46.
Nemaura Medical Debt-to-Equity Historical Data
The historical data trend for Nemaura Medical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nemaura Medical Debt-to-Equity Chart
|
Nemaura Medical Annual Data
|
|
Trend |
Mar14 |
Mar15 |
Mar16 |
Mar17 |
Mar18 |
Mar19 |
Mar20 |
Mar21 |
Mar22 |
Mar23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
2.98 |
41.18 |
-1.70 |
|
Nemaura Medical Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
-2.04 |
-1.70 |
-1.19 |
-1.32 |
-1.10 |
Competitive Comparison of Nemaura Medical's Debt-to-Equity
For the Medical Devices subindustry, Nemaura Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nemaura Medical's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nemaura Medical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nemaura Medical's Debt-to-Equity falls into.
Nemaura Medical Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Nemaura Medical's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as
Nemaura Medical's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nemaura Medical (Nemaura Medical) Business Description
Traded in Other Exchanges
N/A
Address
57 West 57th Street, New York, NY, USA, 10019
Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. SugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with an app displaying glucose readings at five-minute intervals for periods up to 24 hours.
Executives
| Bashir Timol |
director, 10 percent owner, officer: Chief Business Officer |
C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT |
| Chowdhury Dewan Fazlul Hoque |
director, 10 percent owner, officer: CEO & President |
CHAMWOOD BUILDING, HOLYWELL PARK, ASHBURY ROAD, LOUGHBOROUGH LEICS X0 LE113AQ |
| Salim Natha |
director |
LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF |
| Justin James Mclarney |
officer: Chief Financial Officer |
C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019 |
| Sufyan Ismail |
10 percent owner |
C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT |
| Thomas Peter Moore |
director |
C/O NEMAURA MEDICAL, INC., 57 WEST 57TH STREET, MANHATTAN NY 10019 |
| Timothy Christopher Johnson |
director |
C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019 |
| Iain Anderson |
officer: CFO |
LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF |
| Kathryn Farrar |
officer: Director of Finance |
C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT |
| Julie Pomeroy |
officer: Director of Finance |
C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT |
| Richard Toon |
officer: Technical & Bus. Dev. Manager |
C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT |
Nemaura Medical (Nemaura Medical) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NMRD has been successfully added to your